Zealand Pharma A/s Stock
Zealand Pharma A/s Stock
A loss of -2.340% shows a downward development for Zealand Pharma A/s.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Zealand Pharma A/s stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Zealand Pharma A/s in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
B****
Cons
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Zealand Pharma A/s vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Zealand Pharma A/s | -2.340% | 4.316% | 22.829% | -1.254% | -28.603% | 42.217% | 99.650% |
| Saniona AB | -1.340% | -1.080% | 3.927% | 60.081% | -37.904% | 54.876% | -31.156% |
| NanoViricides Inc. | 0.870% | -6.400% | -17.606% | -9.302% | 25.806% | 0.000% | -64.631% |
| Ocuphire Pharma Inc. | 0.620% | 4.348% | -2.890% | 251.464% | 99.762% | -13.625% | -17.647% |
News
Sensus Healthcare Q2 Earnings Call Highlights
Key Points
- Interested in Sensus Healthcare, Inc.? Here are five stocks we like better.
- Second-quarter revenue fell sharply to $2.3 million from $7.3 million a year earlier, primarily because
Merlin, Inc. Common Stock Q2 Earnings Call Highlights
Key Points
- Interested in Merlin, Inc. Common Stock? Here are five stocks we like better.
- Second-quarter revenue rose to approximately $2.2 million, up $1.2 million sequentially, while Merlin
Entain H1 Earnings Call Highlights
Key Points
- Interested in Entain Plc? Here are five stocks we like better.
- Entain reported strong first-half growth: Online net gaming revenue increased 7% in constant currency, group EBITDA